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Abstract 
Mood disorders and circulating thyroid antibodies are very prevalent in the population and their concomitant 
occurrence may be due to chance. However, thyroid antibodies have been repeatedly hypothesized to play a role 
in specific forms of mood disorders. Potentially related forms include treatment-refractory cases, severe or atypical 
depression, and depression at specific phases of a woman’s life (early gestation, postpartum depression, perimeno-
pausal). With regard to bipolar disorder, studies of specific subgroups (rapid cycling, mixed, or depressive bipolar) have 
reported associations with thyroid antibodies. Offspring of bipolar subjects were found more vulnerable to develop 
thyroid antibodies independently from the vulnerability to develop psychiatric disorders. A twin study suggested thy-
roid antibodies among possible endophenotypes for bipolar disorder. Severe encephalopathies have been reported 
in association with Hashimoto’s thyroiditis. Cases with pure psychiatric presentation are being reported, the antithy-
roid antibodies being probably markers of some other autoimmune disorders affecting the brain. Vasculitis resulting 
in abnormalities in cortical perfusion is one of the possible mechanisms.
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Review
The association between thyroid function disorders and 
neuropsychiatric manifestations has long been known. 
Bauer et  al. (2008) have reviewed such a relationship in 
patients with primary thyroid disease and primary mood 
disorders. The most obvious interactions are between 
hypothyroidism and depressive symptoms and between 
hyperthyroidism and manic/hypomanic symptoms. 
However, there may be exceptions to this simple rule.
Over the last decades, special interest has been devoted 
to autoimmune thyroid disease and circulating thyroid 
antibodies. Autoimmune thyroiditis and Graves’ disease 
are the two major forms of autoimmune thyroid disease. 
Autoimmune thyroiditis may be associated with the 
entire spectrum of function (overt hypothyroidism, sub-
clinical hypothyroidism, thyrotoxicosis), but has recently 
been associated with neuropsychiatric manifestations 
even in the absence of thyroid hormone abnormalities 
(for a review see Leyhe and Müssig 2014).
The role of thyroid antibodies in neuropsychiatry has 
been investigated only recently. In fact, early studies 
reporting the neuropsychiatric consequences of thyroid 
dysfunction were not able to investigate the status of cir-
culating thyroid antibodies, whose role might have been 
overlooked. One of the reasons is that, even if the com-
monest form of thyroiditis was first described more than 
one century ago by Hashimoto (1912), its autoimmune 
nature was discovered only in 1956 (Campbell et al. 1956) 
and it took several decades before methods of detection 
of thyroid antibodies were to be part of clinical practice, 
especially in psychiatry.
Hashimoto’s thyroiditis
Hashimoto’s thyroiditis is a chronic autoimmune inflam-
mation of the thyroid gland. The diagnosis is suspected 
based on the detection of elevated levels of circulating 
antithyroid autoantibodies. The diagnosis of thyroiditis 
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is confirmed when fine needle aspiration biopsy, histol-
ogy from thyroidectomy, or autopsy shows lymphocytic 
infiltration of the thyroid gland. The first to describe 
lymphocytic infiltration was the Japanese surgeon Hashi-
moto (1912), after whom the disease was named. Patients 
with lymphocytic thyroiditis may have various circulat-
ing autoantibodies, including antibodies against thyroid 
peroxidase (AbTPO), thyroglobulin (AbTG), and thyroid-
stimulating hormone (TSH) receptors. Studies published 
until the late 1980s referred to thyroid microsomal anti-
bodies (AbM), the fraction that turned out to be specific 
for AbTPO (Mariotti et al. 1987). A chronic autoimmune 
thyroiditis is reported by post-mortem studies in 27  % 
of adult women (with a peak in subjects over 50 years), 
and 7 % of adult men; diffuse changes are found in 5 % 
of women and 1  % of men (Vanderpump 2005). Hypo-
echoic or irregular ultrasound patterns in the presence of 
AbM titers ≥1:400 are considered diagnostic for Hashi-
moto’s thyroiditis (Marcocci et al. 1991). However, 20 % 
of individuals with an ultrasound pattern suggestive of 
thyroiditis are antibody negative (Marcocci et  al. 1991). 
Moreover, circulating antibodies may be present in sub-
jects with no evidence of thyroiditis (for a review see 
Biondi and Cooper 2008).
Even if the entire spectrum of thyroid function may be 
observed, Hashimoto’s thyroiditis is the most frequent 
cause of hypothyroidism in areas of sufficient iodine 
intake (Vanderpump and Tunbridge 2002; Hollowell 
et  al. 2002). However, in its acute phase, it can cause a 
transient hyperthyroidism resulting from the inflamma-
tion process and the subsequent liberation of preformed 
thyroid hormones (Fatourechi et  al. 1971). AbTG alone 
in the absence of AbTPO are not usually associated with 
thyroid dysfunction (Hollowell et al. 2002).
Prevalence of circulating antithyroid antibodies in patients 
with mood disorders
Several studies have surveyed the prevalence of circu-
lating antithyroid antibodies in psychiatric populations 
(principal results are summarized in Table 1). Gold et al. 
(1982) were the first to hypothesize that the so-called 
symptomless autoimmune thyroiditis may be not symp-
tomless. Their hypothesis was based on the finding that 
the majority (60 %) of patients admitted to a psychiatric 
hospital for depression (or lack of energy) and thyroid 
dysfunction had circulating AbM (titer ≥1:10). It must 
be said, however, that patients had been diagnosed with 
subclinical, mild, or overt hypothyroidism, but no other 
evidence of thyroiditis was mentioned. Moreover, the 
overall prevalence of AbM in their patients was 9/100, 
which may be similar to the prevalence reported for the 
general population, especially if such low titers (≥1:10) 
are considered positive.
Despite using often the term autoimmune thyroiditis, 
subsequent studies focused on the mere presence of cir-
culating antibodies. Ultrasound support was provided in 
some study (Custro et  al. 1994), but no study provided 
cytological or histological evidence of thyroiditis.
Prevalence studies published in the last two decades 
have generally included normal controls and investigated 
the presence of the more specific AbTPO (Table 1). Some 
authors have used concentration of antibodies (or their 
log-transformed titers) as a continuous variable rather 
than the positive/negative dichotomy (Hornig et  al. 
1999).
The large Dutch study by Oomen et  al. (1996) exam-
ined thyroid function tests, including AbTPO, in serum 
collected 2–3  weeks after hospitalization from 3756 
psychiatric patients in 1987–1990. The prevalence of 
positive AbTPO was related to age and sex. The rate 
in the overall psychiatric sample was 331/3316 (10  %). 
In the subgroup older than 55  years, prevalence rates 
found in patients with any psychiatric hospitaliza-
tion (131/968 =  13.5 %) were similar to those found in 
healthy individuals living in the same area and matched 
by age (258/1877 = 13.7 %). With regard to bipolar dis-
order, the Dutch study addressed some specific issues, 
such as lithium exposure and rapid cycling (principal 
data are summarized in Table  2). In particular, among 
50 AbTPO positive cases, affective disorders and not 
other psychiatric diagnoses (dementia, schizophrenia, 
etc.) were overrepresented (44  %) compared with the 
subgroup of 83 with normal thyroid parameters (25 %). 
The most significant association was between antibody 
positivity and the subgroup with rapid cycling bipolar 
disorder. Rapid cycling was diagnosed in 8/45 (18  %) 
antibody-positive patients and in none of the 76 patients 
with normal thyroid parameters. The disproportion was 
maintained after controlling for prior treatment known 
to influence thyroid function, including lithium. Results 
contrasted with those from an earlier small study which 
did not reveal differences in the prevalence of circulating 
thyroid antibodies between 11 women with rapid cycling 
and 11 with non-rapid cycling bipolar disorder (Bartal-
ena et al. 1990).
Outpatients with bipolar disorder from the Stanley 
Foundation Bipolar Network, a multicenter longitudinal 
treatment research program performed in the United 
States and the Netherlands (Kupka et  al. 2002), were 
assessed for the prevalence of AbTPO and thyroid failure. 
The study included 226 outpatients with bipolar disorder, 
252 control subjects from the general population, and 
3190 psychiatric inpatients of any diagnosis. AbTPO were 
more prevalent (28 %) in bipolar patients than in popula-
tion and psychiatric controls (3–18  %). The presence of 
circulating antibodies in bipolar patients was associated 
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with thyroid failure, but not with age, gender (28.9 % of 
women, 27.7  % of men), current mood state (euthymia, 
depression, hypomania/mania, or mixed state), and rapid 
cycling in the past year.
In a small exploratory study of 30 major depressive 
patients, Fountoulakis et  al. (2004) reported a signifi-
cantly higher proportion of AbM in depressed patients 
with atypical features (according to DSM-IV) (N  =  10) 
compared with healthy controls.
Leyhe et al. (2009) found that the proportion of a clini-
cally severe degree of depressive episode was signifi-
cantly higher among patients with thyroid autoantibodies 
(63.2 %) compared with patients with negative antibodies 
(28.6 %).
Degner et al. (2015) found circulating AbTPO in 17/52 
(32.7  %) outpatients with uni- or bi-polar depression. 
The odds ratio for autoimmune thyroiditis (which was 
confirmed by a hypoechoic pattern in ultrasonography) 
was ten times higher when compared with 19 outpatients 
with schizophrenia.
The presence of thyroid autoantibodies was also asso-
ciated with poor response to antidepressant therapy 
(Browne et al. 1990; Eller et al. 2010).
Related studies
In a pilot study, Rubino et  al. (2004) tested the hypoth-
esis of a relationship between bipolar disorder and auto-
immune thyroiditis by assessing three groups of women 
with the Serial Color-Word Test (Smith and Klein 1953). 
The latter consists in the analysis of reading times during 
the repeated confrontation with the Stroop task, i.e., the 
interference between reading the names and naming the 
colors of incongruent color-words. A discontinuous style 
of adaptation to the conflict situation was more marked 
in the group of remitted bipolar subjects compared 
with the group with autoimmune thyroiditis, and more 
marked among the latter than among non-clinical con-
trols. Diagnosis of autoimmune thyroiditis was defined 
clinically with no mention of particular procedures 
except the presence of AbTPO.
Table 1 Prevalence studies of thyroid antibodies in patients with mood disorders
Authors Antibody Bipolar disorder Major depression Other Normal controls
Gold et al. (1982) AbM – – Hospitalized for depres-
sion or lack of energy 
9/100 (9 %)
–
Nemeroff et al. (1985) AbM and/or AbTG 0/3 (0 %) 7/28 (25 %) Any hospitalized with 
prominent depres-
sive symptoms 9/45 
(20 %)
–
Joffe (1987) AbM and/or AbTG – 5/58 (8.6 %) – –
Haggerty et al. (1990) AbM and/or AbTG 4/31 (13 %) 5/65 (8 %) Non-affective disorders 
7/68 (10 %)
–
Custro et al. (1994) AbTPO and/or AbTG – 5/9 (56 %) Minor depression 0/66 
(0 %)
1/38 (3 %)
Haggerty et al. (1997) AbM and/or AbTG Mixed 5/26 (19 %)
Depressed 3/19 (16 %)
Manic 2/51 (3.9 %)
15/218 (6.9 %) Adjustment disorder 
2/80 (2.5 %)
10/144 (6.9 %)
König et al. (1999) AbTPO or AbM and/or 
AbTG
– Severe, hospitalized 
100/144 (70 %)
– –
Kupka et al. (2002) AbTPO 64/226 (28.3 %) – Any psychiatric hospi-
talization 324/3190 
(10.2 %)
23–34/252 (9.1–13.5 %) 
range with different 
assays
Brouwer et al. (2005) AbTPO – Outpatients 9/113 (8 %) – 11/113 (10 %)
Degner et al. (2015) AbTPO and/or AbTG 4/13 (30.8 %) 12/39 (38.5 %) Schizophrenia 2/19 
(10.5 %)
–
Table 2 Principal data from Oomen et al. (1996)
Affective 
disorders
Lithium-naïve affective  
disorders
Rapid cycling  
bipolar disorder
Lithium-naïve rapid 
cycling bipolar disorder
Normal thyroid function 21/83 (25 %) 16/76 (21 %) 3/83 (4 %) 0/76 (0 %)
AbTPO positive 22/50 (44 %) 17/45 (38 %) 12/50 (24 %) 8/45 (18 %)
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Geracioti et al. (2003) described a patient with classic 
borderline personality disorder whose fluctuating mood 
and psychotic symptoms were directly linked to AbTG 
titers determined over a period of 275 days.
Community studies
Several studies have investigated the relationships 
between circulating thyroid antibodies and mood disor-
ders at the community level. In this case, data regarded 
principally depression. Pop et al. (1998) studied 583 peri-
menopausal women randomly selected from a commu-
nity cohort in the Netherlands. Depression (defined as a 
score of 12 or higher in the self-rating Edinburgh Depres-
sion Scale) was found in 134 cases (23  %) and AbTPO 
in 58 cases (10  %). Multiple logistic regression analy-
sis supported an association between positive AbTPO 
and depression (odds ratio 3.0; 95 % confidence interval 
1.3–6.8).
Kuijpens et  al. (2001) studied prospectively 310 unse-
lected women during gestation and up to 36 weeks post-
partum. The presence of AbTPO was independently 
associated with depression at 12-week gestation and at 4 
and 12  weeks postpartum (odds ratios between 2.4 and 
3.8). After the exclusion of women who were depressed 
at 12-week gestation or had had depression in earlier life, 
the presence of AbTPO during early gestation was still 
associated with postpartum depression (odds ratio 2.9).
The same group reported a prospective follow-up of 
1017 pregnant women from the general population (Pop 
et al. 2006). The presence of thyroid antibodies was asso-
ciated with major depression during early gestation (12 
and 24 weeks) but not at the end of term, when there is 
maximal downregulation of the immune system.
Carta et al. (2004), in a smaller community-based study, 
found AbTPO in 13 of 42 (31 %) subjects with mood dis-
order, in 15 of 41 (37 %) with anxiety disorder, and in 19 
of 139 (14 %) with no psychiatric disorder. Using multi-
variate logistic regression, associations were significant 
between thyroid antibodies and anxiety disorders (odds 
ratio 4.2; 95 % confidence interval 1.9–38.8) or mood dis-
order (odds ratio 2.9; 95 % confidence interval 1.4–6.6).
On the contrary, a large population-based study using 
a self-report symptom scale for depression and anxiety 
found no association with antithyroid antibodies (Engum 
et al. 2005). The prevalence of depression in individuals 
with positive AbTPO (115/995  =  11.6  %) did not dif-
fer from the prevalence found in the general population 
(385/29,180 = 13.2 %).
The role of AbTPO (independent of overt thyroid 
dysfunction) has also been investigated in postpartum 
depression in both clinical and community settings. 
Some studies supported an association (Pop et al. 1993; 
Harris et al. 1992; Lazarus et al. 1996), while others could 
not demonstrate it (Stewart et al. 1988; Kent et al. 1999).
Family and twin studies
Hillegers et al. (2007) studied children of bipolar parents 
and found circulating AbTPO in 9 of 57 (16  %) daugh-
ters. The latter prevalence was higher than that found in 
matched controls (4/103 = 4 %). As the presence of anti-
bodies was not associated with mood disorder (or any 
psychopathology) in the offspring, the authors suggested 
that offspring of bipolar subjects are more vulnerable to 
develop thyroid antibodies independently from the vul-
nerability to develop psychiatric disorders.
Vonk et al. (2007) studied 22 monozygotic and 29 dizy-
gotic bipolar twins and 35 healthy matched control twins. 
Circulating AbTPO were found in 27  % of the bipolar 
index twins, 29  % of the monozygotic bipolar cotwins, 
27  % of the monozygotic non-bipolar cotwins, 25  % of 
the dizygotic bipolar cotwins, 17 % of the dizygotic non-
bipolar cotwins, and in 16  % of the control twins. The 
conclusion was that thyroid antibodies are related not 
only to bipolar disorder but also to the genetic vulner-
ability to develop the disorder. The authors proposed 
autoimmune thyroiditis as a possible endophenotype for 
bipolar disorder.
Thyroid autoimmunity and lithium treatment
Lithium has long been known to interact with thyroid 
function (for reviews see Lazarus 1998; Bocchetta and 
Loviselli 2006). Moreover, lithium affects many aspects of 
cellular and humoral immunity in vitro and in vivo, but 
it is controversial whether lithium per se can induce thy-
roid autoimmunity. In a prospective study, Lazarus et al. 
(1986) observed significant fluctuations in antibody titer, 
both upwards and downwards in 10/12 patients with 
AbM and in 9/11 with AbTG treated with lithium for a 
mean of 16.2 months. The fluctuations in antibody titer 
are consistent with an immunomodulatory effect of lith-
ium as has been shown in animal studies (for a review see 
Lazarus 1998).
Other prospective studies, although reporting fluc-
tuations in antibody titers, failed to detect differences 
between pre- and post-lithium prevalence rates (Myers 
et al. 1985; Calabrese et al. 1985).
Prevalence of circulating thyroid antibodies among 
lithium-treated patients varies across studies. It is, how-
ever, important to underline once again the effects of 
age and sex. Initial and final prevalence rates of AbM/
AbTPO and/or AbTG from our Sardinian lithium cohort 
followed up for 15  years (Bocchetta et  al. 2001, 2007a) 
(women, 21–28 %; men, 4–10 %) were within the ranges 
observed in similar age and sex subgroups of the general 
Page 5 of 18Bocchetta et al. Int J Bipolar Disord  (2016) 4:5 
population. In fact, a Sardinian survey reported an over-
all prevalence of AbTPO of 174/789 (22.0  %) in women 
and 30/444 (6.7 %) in men (Loviselli et al. 1999).
Annual incidence rates in patients after several years of 
lithium treatment (1.4–1.8 %) (Bocchetta et al. 2007a) did 
not much differ from the ranges of incidence reported for 
the general population, with maximum values of approxi-
mately 2 % per year in women aged over 45 (Vanderpump 
et al. 1995; Tunbridge et al. 1981).
As mentioned above, circulating thyroid antibodies 
have been found associated with affective disorders irre-
spective of treatment (Oomen et al. 1996).
In their prospective study, Lazarus et al. (1986) found 
that 16/37 (43  %) manic depressive patients had, before 
receiving lithium therapy, either AbM or AbTg or both.
According to Kupka et al. (2002), prevalence of circu-
lating thyroid antibodies was not associated with prior 
lithium exposure. Indeed, AbTPO were found positive in 
12/35 (34.3 %) patients who had never received lithium, 
a prevalence even higher than that found in the overall 
sample of bipolar outpatients (64/226 = 28 %).
In a cross-sectional study from the Berlin area, Baethge 
et  al. (2005) did not find increased prevalence of circu-
lating thyroid antibodies between a group of 100 adult 
patients with mood disorders undergoing lithium therapy 
(AbTPO 7/100 = 7 %; AbTG 8/100 = 8 %) and 100 age- 
and sex-matched controls with no history of psychiatric 
disorder (AbTPO 11/100 = 11 %; AbTG 15/100 = 15 %). 
In a prospective account of the Sardinian lithium cohort 
study, we reported the appearance of circulating thyroid 
antibodies in young subjects of both sexes within a few 
years of lithium exposure (Bocchetta et  al. 1992). The 
presence of mild ultrasound thyroid abnormalities before 
lithium predicted the appearance of circulating antibod-
ies (Loviselli et  al. 1997). All antibody-positive lithium 
patients (12 women, one man) who underwent ultrasonic 
scan displayed a hypoechoic pattern and 11/13 (85 %) also 
presented a non-homogeneous echopattern; however, 
also the majority of antibody-negative lithium patients 
(31/32 = 97 % of women; 11/16 = 69 % of men) presented 
ultrasound abnormalities (Bocchetta et al. 1996).
Van Melick et al. (2010) found AbTPO and/or AbTG in 
12/45 (27 %) lithium patients of 65 years and older, which 
did not differ from the prevalence found in the same age 
group in the general population.
Kraszewska et  al. (2015) studied 66 patients (mean 
age, 62 years) with bipolar disorder receiving lithium for 
10–44  years and found AbTPO in 30 cases (45  %) and 
AbTG in 43 cases (65 %).
Hashimoto’s encephalopathy
The first description of neuropsychiatric disease associ-
ated with autoimmune thyroid dysfunction was by Brain 
et  al. (1966). They described the case of a 40-year-old 
coachbuilder with known thyroid antibody-positive 
Hashimoto’s disease who subsequently developed focal 
neurological deficits and coma successfully treated with 
steroids and thyroxine replacement.
Subsequently, involvement of CNS in patients with 
thyroiditis has been reported repeatedly, resulting in the 
proposal of the term “Hashimoto’s encephalopathy” by 
Shaw et al. (1991).
Some authors have commented that there is no evi-
dence of a pathogenic role for the antibodies, which are 
probably markers of some other autoimmune disorders 
affecting the brain (Chong et al. 2003; Fatourechi 2005). 
The term “steroid-responsive encephalopathy associ-
ated with autoimmune thyroiditis” (SREAT) has been 
proposed (Castillo et  al. 2006). Clinical presentations 
and course vary (for a review see Marshall and Doyle 
2006). Onset may be acute or subacute. Presentation may 
include alteration of conscious level, seizures, tremor, 
myoclonus, ataxia, or multiple stroke-like episodes.
Psychiatric symptoms, including depression and psy-
chosis, have also been reported (Rolland and Chevrollier 
2001; Laske et al. 2005; Mahmud et al. 2003). For a recent 
review on cognitive and affective dysfunctions in autoim-
mune thyroiditis, see Leyhe and Müssig (2014).
Course of encephalopathy may be relapsing/remitting 
or progressive, even evolving into dementia. Pathological 
EEG and non-specific imaging abnormalities may be pre-
sent. Brain MRI findings may change abruptly and drasti-
cally. For example, reversible MRI lesions in the cerebral 
white matter, supposedly reflecting brain edema, have 
been reported in one case where antithyroid antibodies 
were also detected in the cerebrospinal fluid (Wakai et al. 
2004).
To our knowledge, twelve cases have been reported 
to date where a prominent psychiatric presentation was 
associated with autoimmune thyroiditis (Table  3). The 
majority of cases were characterized by abnormal thy-
roid function (seven hypothyroidism; two hyperthy-
roidism), but the diagnosis of thyroiditis was supported 
by ultrasonography only in half the cases. In one case 
(Schmidt et  al. 1990), thyroid hormone replacement 
alone resolved the mood disorder. In the two postpar-
tum psychoses (Bokhari et  al. 1998; Stowell and Barn-
hill 2005), antipsychotics were necessary in combination 
with thyroid treatment. For example, in the case with 
hyperthyroidism (Bokhari et  al. 1998) the patient, who 
had presented with delusions, hallucinations, mixed 
mood symptoms, agitation, and transient disorienta-
tion, responded to loxapine and amoxapine, after achiev-
ing biochemical euthyroidism with propylthiouracil. In 
other cases, corticosteroids were also administered. For 
example, Mahmud et  al. (2003) described the case of a 
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14-year-old girl who presented with a 5-year history of 
hallucinations and depression, elevated AbTPO, MRI 
white matter changes affecting the frontal lobe, and cer-
ebral hypoperfusion shown with single-photon emission 
computed tomography (SPECT). The patient had sig-
nificant clinical improvement and showed resolution on 
neuroimaging after methylprednisolone treatment. The 
74-year-old woman with antidepressant-resistant depres-
sion, reported by Laske et al. (2005), who also had EEG 
abnormalities, was successfully treated with predniso-
lone as an add-on to venlafaxine therapy. The 46-year-old 
man reported by Liu et al. (2011), who presented with an 
acute depressive episode, mild diffuse cortical dysfunc-
tion on EEG, and hypothyroidism with the presence of 
thyroid antibodies in both serum and CSF, was success-
fully treated with thyroid hormone replacement and 
methylprednisolone.
The manic episode claimed to represent the first case 
of bipolar disorder due to Hashimoto’s encephalopathy 
(Müssig et al. 2005), was associated with hyperthyroidism 
and pathological EEG. The patient responded to psychi-
atric treatment, carbimazole and short-term treatment 
with high doses of prednisolone.
In the subsequent cases of mania reported in asso-
ciation with autoimmune thyroiditis, most attention was 
drawn to the hypothyroid status of the patient rather 
than to autoimmunity.
The case of acute mania precipitated by hypothyroid-
ism secondary to postpartum thyroiditis (Stowell and 
Barnhill 2005) responded to levothyroxine and risp-
eridone. The elderly Chinese woman with late-onset 
psychotic mania precipitated by autoimmune hypothy-
roidism (Tor et  al. 2007) was treated successfully with 
levothyroxine and low-dose haloperidol. Lin et al. (2011) 
reported in Taiwan a case of Hashimoto’s encephalopathy 
with manic symptoms that responded to levothyroxine, 
prednisolone in addition to olanzapine and valproate. The 
patient had undergone partial thyroidectomy 22  years 
earlier for a hyperthyroid goiter, but histology findings 
were not reported. A different group in Taiwan reported 
Table 3 Case reports of autoimmune thyroiditis associated with mood disorder
Authors Presentation Sex and 
age
TSH  
(µU/ml)
Antibody titer  
(normal range)
Treatment
Schmidt et al. (1990) Menstrual related mood 
disorder
F 37 12.1 AbM 1/1600 (<1/100)
AbTG 1/10 (<1/10)
Levothyroxine
Bokhari et al. (1998) Postpartum psychosis F 29 <0.03 AbTPO 2330 (0–100)
AbTG 597 (0–100)
Loxapine, amoxapine, pro-
pranolol, propylthiouracil
Mahmud et al. (2003) Psychotic depression F 14 77.4 AbTPO 6320 (0–20) Psychotropic medication as 
before (valproate, sertraline, 
quetiapine) plus levothyrox-
ine, methylprednisolone
Müssig et al. (2005) Manic episode F 32 <0.03 AbTPO 2010 (0–2)
AbTG 1.1 (0–1)
Psychotropic medication as 
before (quetiapine, lithium, 
mirtazapine, venlafax-
ine) plus reboxetine and 
transcranial magnetic 
stimulation, carbimazole, 
prednisolone
Laske et al. (2005) Severe depressive episode F 74 Normal AbTPO 842 (0–2) Prednisolone, venlafaxine as 
before
Stowell and Barnhill (2005) Postpartum psychotic acute 
mania
F 35 >150 AbTPO significantly elevated Levothyroxine and risperidone
Tor et al. (2007) Late-onset psychotic mania F 72 79.4 AbTPO 50 (0–50)
AbTG 2507 IU/ml (0–40)
Levothyroxine and low-dose 
haloperidol
Bocchetta et al. (2007b) Affective psychosis F 43 1.24 AbTPO>1000 (0–35)
AbTG normal
Levothyroxine as before, 
valproate discontinuation, 
lithium plus olanzapine
Nagamine et al. (2008) Lithium-induced encepha-
lopathy
F 61 2.15 AbTPO 50 (0–0.3)
AbTG 1/25,600 (1/100)
Methylprednisolone, 
levothyroxine as before, 
lithium discontinuation
Liu et al. (2011) Acute depressive episode M 46 66.7 AbTPO 1698 (0–5.61)
AbTG 154 IU/ml (0–14.4)
Levothyroxine, methylpred-
nisolone
Lin et al. (2011) Manic symptoms F 52 50.71 AbTPO 1652 (0–25)
AbTG 296 IU/ml (0–25)
Levothyroxine, prednisolone, 
olanzapine and valproate
Lin et al. (2013) Acute mania F 41 18.79 AbTPO 411 (0–60)
AbTG 296 IU/ml (0–60)
Levothyroxine, valproate and 
quetiapine
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acute mania in a 41-year-old woman with no history 
of psychiatric illness. Both mania and hypothyroidism 
(resulting from Hashimoto’s thyroiditis as confirmed by 
diffusely heterogeneous and hypoechoic pattern in ultra-
sonography and lymphoid cell infiltration in fine needle 
aspiration cytology), remitted gradually within 3  weeks 
after treatment with levothyroxine, valproate, and quetia-
pine (Lin et al. 2013).
Case series
Following our first case report of treatment-refractory 
affective psychosis (Bocchetta et al. 2007b), we started to 
collect additional cases with psychiatric presentation and 
autoimmune thyroiditis.
First, we provide here a follow-up of our published 
case (Bocchetta et al. 2007b): the patient was a 43-year-
old woman, with a history of recurrent depression since 
the age of 31, who had developed manic, psychotic, and 
soft neurological symptoms across the previous 3  years 
in concomitance with her first diagnosis of Hashimoto’s 
thyroiditis. Brain MRI had evidenced several non-active 
lesions in the white matter from both hemispheres, sug-
gestive of a non-specific past vasculitis. Brain SPECT 
had showed cortical perfusion asymmetry particularly 
between frontal lobes. Nailfold videocapillaroscopy had 
evidenced a reduced number of capillaries and an irregu-
larity in pattern, consistent with past vasculitis. Over the 
following 10 years, the patient has been maintained with 
a combination of lithium, olanzapine, bupropione, citalo-
pram, and benzodiazepines. Functioning has improved 
although not returning to pre-morbid levels. In particu-
lar, she has not manifested psychotic symptoms any more 
and her suicidality has gradually disappeared. Current 
status is characterized by mild anxiety and impairment 
in memory retrieval. The latter cognitive impairment 
remained unchanged during and after 4-week therapy 
with methylprednisolone (maximum dose 16  mg/daily) 
prescribed by the dermatologist for recurrence of her 
urticaria vasculitis. Thyroid function has been main-
tained adequately with levothyroxine replacement. 
AbTPO titers have remained elevated (last measurement 
>1000  IU/ml; normal range 0–35  IU/ml) with normal 
AbTG.
The series summarized in Table  4 regards patients 
visited at our psychopharmacology unit over the last 
20  years and is limited to cases with antibody titers 
clearly exceeding the upper end of the normal range. The 
diagnosis of thyroiditis was supported by ultrasonic scan. 
In two cases, the diagnosis of thyroiditis was confirmed 
with cytology by fine needle aspiration biopsy (case # 8) 
or histology after thyroidectomy (case # 1).
In some cases, further diagnostic procedures were 
undertaken, especially when (a) response to psychiatric 
treatment was poor; (b) cognitive or neurological symp-
toms were prominent; and (c) in attempts at investigating 
potential pathogenic links. The following details regard 
cases with noteworthy findings.
Case # 1
A 65-year-old woman was referred to our unit for moni-
toring of valproate therapy. Lithium treatment had been 
stopped after 1-year trial because the patient had used 
a lithium overdose in one of her many suicide attempts. 
She had undergone thyroidectomy 2  years earlier and 
was under adequate replacement with levothyroxine. 
Response to valproate had been partial and she was on 
a combined therapy with antipsychotics. Given the pres-
ence of cognitive impairment and limb and head tremor, 
we requested brain MRI. White matter hyperintensities 
consistent with microangiopathy were evidenced close 
to the frontal horns and in the body of lateral ventricles, 
in subcortical right parietal and left frontal and occipi-
tal regions, in the left thalamus and the semioval center. 
Initial enlargement of CSF spaces was also reported. 
Antinuclear antibodies were also evidenced (titer 1:160; 
normal range <1:80). Over the following 5  years, she 
manifested recurrent episodes of depressed mood, time 
and place disorientation, wandering, impairment in 
memory. She also manifested postural and gait instability, 
diffused tremor of head and limbs.
Case # 2
A 54-year-old woman was referred to our unit for moni-
toring of lithium therapy. She had been treated suc-
cessfully with lithium since the age of 42, but thyroid 
function had never been examined. We requested a thy-
roid workup resulting in the diagnosis of autoimmune 
hypothyroidism. Over the next 9 years, the patient com-
plained of impairment in concentration and memory and 
hand and leg tremor. AbTPO titer was invariably elevated 
(around 2000  IU/ml; normal range 0–20  IU/ml). At age 
63, the patient abandoned lithium maintenance, consid-
ering it responsible for the worsening of tremors. Over 
the subsequent 2 years, mood fluctuations become more 
severe and the patient was treated with antidepressants 
and olanzapine. She began to manifest dysarthria and her 
resting tremor worsened. Cognition was further dete-
riorated. She was hospitalized and brain MRI evidenced 
widespread encephalopathy regarding periventricular 
white matter. The patient was again referred to our lith-
ium clinic with a view to lithium’s potential neuroprotec-
tive properties. Over the following 2  years, there was a 
partial stabilization of mood fluctuations with low-dose 
lithium, but cognitive function worsened. Brain MRI 
confirmed prior evidence of white matter encephalopa-
thy, with atrophic widening of ventriculi, CSF spaces, 
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cisternal and cortical sulci, especially in the frontal cor-
tex. At age 69, the patient manifested anomia and impair-
ment in concentration and attention. She had a score of 
12/30 on the mini-mental state examination (MMSE). 
Instrumental activities of daily living (IADL) and activi-
ties of daily living (ADL) were markedly impaired, with 
scores of 2/8 and 4/6, respectively. EEG evidenced 
marked and widespread slow bioelectric abnormalities. 
Brain SPECT with 99mTc-ethyl cysteinate dimer (ECD) 
evidenced non-homogeneous cortical perfusion of both 
hemispheres, regarding particularly left temporal cortex 
and parietal cortex (Fig. 1). Nailfold videocapillaroscopy 
evidenced a “flou” effect (widespread reduced visibility 
of capillaries due to microedema). Capillary loops were 
hypodense or atypical, with meandering and dilatation 
especially at the top. Elongated capillaries were also fre-
quent and sludge was also present. The report concluded 
that the microcirculatory abnormalities were consistent 
with a non-specific organic microangiopathy. We sus-
pected an immune-mediated vasculitis and prescribed 
a trial with corticosteroids. However, treatment was 
abandoned after a few weeks given the onset of diabe-
tes. Cognitive symptoms worsened over the following 
7  years resulting in severe dementia. Lithium has been 
maintained in combination with quetiapine with a partial 
effect on mood swings and behavioral manifestations.
Case # 3
The patient had suffered from a first psychotic episode 
characterized by auditory hallucinations and persecu-
tory delusions at the age of 23. Her symptoms subsided 
with haloperidol, but she manifested extrapyramidal 
side effects. Following a new psychotic manic episode, 
the patient was referred to our lithium clinic at the age 
of 25. Thyroid workup revealed mildly increased TSH 
(5.30 µIU/ml), a diffused goiter, and Hashimoto’s thyroid-
itis (AbTPO titer = 1567 IU/ml; normal range 0–20 IU/
ml). She was prescribed L-thyroxine substitution. After 
an apparent initial response to lithium, the patient 
developed a new psychotic manic episode. As auditory 
hallucinations did not respond to first-generation antip-
sychotics, she was prescribed treatment with clozapine. 
Over the following 18 years, the patient has been main-
tained with clozapine (100–150 mg/die), augmented with 
small doses of haloperidol to counteract the occasional 
reemergence of auditory hallucinations. She has contin-
ued l-thyroxine substitution and thyroid hormones have 
been within the normal range, but AbTPO remained 
elevated (>1000 IU/ml; normal range 0–20 IU/ml). Ultra-
sonic scans of the thyroid gland evidenced a progressive 
reduction of goiter, whereas the echopattern was consist-
ent with chronic autoimmune thyroiditis (non-homoge-
neous, hypoechogenic, showing a fibro-connective plot 
with pseudonodular features). We suspected the pres-
ence of vasculitis and requested further investigation. 
Nailfold videocapillaroscopy evidenced a reduction in the 
number of capillaries, with a non-homogeneous pattern. 
In particular, the tip was the only part visible in one-third 
of capillaries. Brain SPECT with 99mTc-HMPAO (hexa-
methylpropyleneamine oxime) evidenced non-homoge-
neous cortical perfusion of both hemispheres, with no 
specific area of clear hypoperfusion (Fig. 2).
Case # 4
The patient had suffered from a first depressive episode at 
the age of 45. One year later, following an antidepressant-
related switch into hypomania, she was prescribed lith-
ium. She was referred to our lithium clinic at the age of 
51. Medical history revealed that the patient had also suf-
fered from head tremor for many years and had experi-
enced marked weight loss during adolescence. Her basal 
metabolic rate had been studied (it was the only method 
used to investigate thyroid function at that time), and 
found normal. We requested an updated thyroid workup 
that resulted in a diagnosis of euthyroid autoimmune 
thyroiditis. In any case, the endocrinologist prescribed 
TSH-suppressive levothyroxine treatment. Response 
to lithium has been excellent for the following 23 years. 
AbTPO titer has risen up to >1000 IU/ml (normal range 
0–35 IU/ml). Head tremor is still evident.
Case # 5
The patient had started lithium therapy at the age of 
57 and response was excellent. She was referred to our 
Fig. 1 Case # 2. 99mTc-ECD brain SPECT: hypoperfusion in the left 
temporal and parietal region (arrows)
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lithium clinic at the age of 59. Thyroid function had 
never been examined. We requested a thyroid workup 
resulting in the diagnosis of autoimmune thyroiditis. 
Despite her very high antibody titers, thyroid function 
was normal, and no treatment was indicated. Lithium 
concentrations were maintained below 0.5 mmol/l over 
the following 28 years, given the presence of head tremor 
and bradycardia. The patient has remained euthyroid 
without any specific treatment. Her head tremor is still 
present.
Case # 6
The patient had been maintained well with lithium from 
the age of 49 up to the age of 59. Then, the patient aban-
doned lithium prophylaxis worried about the presence 
of a multinodular goiter. Thyroid hormone concen-
trations had been normal during lithium therapy, but 
hyperthyroidism emerged after lithium withdrawal. She 
was treated with methimazole. Thyroid hormone con-
centrations normalized in a few months and antithyroid 
treatment was stopped. One year later, at age 61, mood 
fluctuations became prominent and the patient was 
referred to our lithium clinic. Given the presence of sui-
cidality, we prescribed lithium again. During the follow-
ing 3  years, mood fluctuations were attenuated with a 
combined treatment (lithium, low-dose haloperidol, and 
benzodiazepines). The patient has no longer experienced 
suicidal thoughts. AbTPO titer has repeatedly been found 
>2000  IU/ml (normal range 0–35  IU/ml), with normal 
thyroid hormone concentrations without any other endo-
crinological treatment.
Case # 7
The patient had suffered from chronic depressive schiz-
oaffective disorder since the age of 17. She had failed to 
respond to adequate trials with various antipsychot-
ics, alone or in combination with carbamazepine. Then, 
at the age of 30, she was referred to our unit. Over the 
last 2 years, treatment had consisted in risperidone and 
carbamazepine. Her presentation included auditory hal-
lucinations, persecutory and religious delusions, bizarre 
and aggressive behavior. Negative symptoms were also 
present. The medical workup resulted in the diagnosis 
of euthyroid Hashimoto’s thyroiditis. Psychotropic treat-
ment was gradually changed to clozapine (up to 375 mg/
daily). Negative symptoms and behavioral manifestations 
improved, but auditory hallucinations persisted. Clozap-
ine doses were progressively reduced due to the emer-
gence of obsessive–compulsive symptoms. At age 35, 
because of increasing TSH concentrations, she was pre-
scribed levothyroxine. At age 40, the patient manifested 
exacerbation of psychosis with concomitant depressive 
symptoms and suicidal thoughts. We suspected the pres-
ence of vasculitis associated with her thyroiditis (AbTPO 
titer  =  3150  IU/ml; normal range 0–35  IU/ml), and 
requested further investigation. Nailfold videocapillaros-
copy evidenced meandering and dilatation of capillaries, 
slowed flux and “flou” effect (reduction in the visibility 
of the capillary bed due to microedema). Brain SPECT 
with 99mTc-ECD evidenced non-homogeneous cortical 
perfusion regarding particularly the right occipital lobe 
and both frontal lobes (Fig.  3). We ruled out treatment 
with corticosteroids for several reasons, including the 
evidence of reduced bone mineral intensity on densitom-
etry. Given the history of suicide attempts, we opted for 
adding lithium to clozapine. The patient has been main-
tained for the last 6 years with a combination of lithium 
and clozapine (current dose 100  mg/daily). Behavioral 
and affective symptoms have improved and the patient 
has no longer experienced suicidal thoughts. Auditory 
hallucinations have persisted, but the patient is less pre-
occupied perhaps because she attributes them to her 
impaired perfusion of the brain.
Case # 9
After the diagnosis of autoimmune thyroiditis at age 
37, AbTPO titers remained elevated over the following 
17 years, reaching the highest titer of 862 IU/ml (normal 
range 0–20 IU/ml). At age 50, the patient was diagnosed 
with an autoimmune polyendocrine syndrome character-
ized by thyroiditis, diabetes, and coeliac disease with the 
Fig. 2 Case # 3. 99mTc-HMPAO brain SPECT: non-homogeneous tracer 
uptake in the cortex of both hemispheres
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presence of anti-reticulin, anti-gliadin, and anti-endomy-
sium antibodies.
Case # 14
According to available clinical records, Hashimoto’s thy-
roiditis had been first diagnosed at the age of 44. At the 
same time, coeliac disease was also diagnosed based on 
the presence of anti-gliadin antibodies. Replacement with 
levothyroxine was started at age 45 but did not appear 
to improve mood disorder. After several years of treat-
ment with antidepressants and antipsychotics, valproate 
was prescribed at the age of 51. However, given the pres-
ence of recurrent suicide ideation, lithium was eventu-
ally combined with valproate at the age of 58 with good 
response over the last 3 years.
Discussion
The hypothesis of an interaction between thyroid anti-
bodies and mood disorders was first raised in the early 
1980s. Early studies investigated the prevalence of cir-
culating antibodies in sample of patients with depressive 
disorder. Sample size was generally limited and cut-off 
for antibody positivity was rather low (1:10). Such low 
titers have been associated with the development of thy-
roiditis in prospective community studies (Tunbridge 
et  al. 1981), but they are very prevalent in the general 
population and their concomitant occurrence with other 
common conditions (including mood disorders) may be 
obviously due to chance.
Moreover, such early prevalence studies did not include 
controls, which is a relevant pitfall. In fact, prevalence 
rates vary widely in the general population, depending on 
several reasons, including sex and age distribution, geo-
graphic origin, not to mention variations in the cut-off 
for antibody positivity (Vanderpump et al. 1995; Hollow-
ell et al. 2002; McGrogan et al. 2008).
The overall prevalence in an Italian survey (using a cut-
off of 1:100 for AbM and/or AbTG) was 12.6 % (females, 
17.3 %; males, 7.0 %), and there was a progressive increase 
with age (from 2.4 % in 1–14-year-old children to 21.9 % 
in the 46–55-year range, with little change in older sub-
jects) (Aghini-Lombardi et al. 1999). The reported prev-
alence in the United States healthy population (using 
a competitive immunoassay procedure) was 13  % for 
AbTPO (≥0.5 IU/ml) and 11.5 % for AbTG (≥1.0 IU/ml) 
(Hollowell et al. 2002).
Hornig et  al. (1999) who studied a sample of patients 
with affective disorders for various autoantibodies (anti-
nuclear, anti-double stranded DNA, anticardiolipin, and 
antithyroid) warned of the potentially misleading influ-
ence of age and sex in prevalence studies.
With regard to antithyroid antibodies and thyroiditis, 
middle-aged women are known to show the highest prev-
alence rates (Vanderpump 2005). Sex differences in thy-
roid dysfunction are very relevant even with regard to the 
diagnosis and treatment of mood disorders, as recently 
reviewed by Bauer et al. (2014).
Overall, the association of thyroid circulating autoan-
tibodies with not otherwise specified mood disorders 
cannot be considered clearly established. The discrepan-
cies across studies may depend on the heterogeneity of 
samples with regard to age, sex, ethnicity, study setting, 
or severity of the mood disorder. On the contrary, clini-
cal samples and community studies have begun to reveal 
increased prevalence of circulating thyroid antibodies 
in the following forms of mood disorders: treatment-
refractory cases (Browne et  al. 1990; Eller et  al. 2010), 
severe (Custro et al. 1994; König et al. 1999; Leyhe et al. 
2009) or atypical depression (Fountoulakis et  al. 2004), 
and depression at specific phases of a woman’s life (early 
gestation, postpartum depression, perimenopausal) (Pop 
et al. 1993, 1998, 2006; Kuijpens et al. 2001; Harris et al. 
1992; Lazarus et al. 1996).
With regard to bipolar disorder, sample size was small 
in several studies from clinical settings (Nemeroff et  al. 
1985; Haggerty et  al. 1990; Bartalena et  al. 1990; Deg-
ner et al. 2015), whereas community studies are not the 
proper instrument for bipolar disorder. In fact, as under-
scored by Carta and Angst (2005), manic/hypomanic 
episodes may be missed in epidemiological surveys, espe-
cially when the subject is the only source of information.
The first suggestion of a potential association between 
bipolar spectrum disorders and circulating thyroid anti-
bodies was published by Haggerty et  al. (1997), who 
Fig. 3 Case # 7. 99mTc-ECD brain SPECT: decreased tracer uptake in 
both frontal lobes and in the right occipital region (arrows)
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reported increased prevalence of AbM and/or AbTG in 
specific subgroups (rapid cycling, mixed, or depressive 
bipolar) compared with healthy individuals controlled for 
age and sex.
One study of a large bipolar sample supported the asso-
ciation of circulating AbTPO with rapid cycling (Oomen 
et al. 1996). Kupka et al. (2002) found an excessive preva-
lence of circulating AbTPO (28 %) in their overall bipo-
lar sample (N = 226) compared with controls. The high 
prevalence of thyroid antibodies found in bipolar men 
(27.7  % compared with 28.9  % in women) represents a 
rare exception to the female predominance.
The following two other lines of evidence support the 
relationship between thyroid antibodies and bipolar dis-
order: (a) in the offspring of bipolar subjects, the vulner-
ability to develop thyroid autoimmunity appears to be 
independent from the vulnerability to develop psychi-
atric disorders (Hillegers et al. 2007); (b) the twin study 
(Vonk et  al. 2007) suggests autoimmune thyroiditis as a 
possible endophenotype for bipolar disorder. It must be 
underscored that the diagnosis of thyroiditis in the latter 
two studies was not supported by further diagnostic pro-
cedures apart from the presence of circulating antibodies.
“Hashimoto’s mood disorders”?
Despite the uncertainty of their role, the presence of thy-
roid antibodies in severe cases of affective disorders can-
not be disregarded. Müssig et al. (2005) claimed that their 
report represents the first case of bipolar disorder due 
to Hashimoto’s encephalopathy. In our own published 
case report, Hashimoto’s thyroiditis was suspected to be 
involved in the deteriorating course of bipolar affective 
psychosis (Bocchetta et al. 2007b). At that time, we spec-
ulated that the rare severe cases of Hashimoto’s encepha-
lopathy presenting with mood disorder may represent 
only the tip of an iceberg. Our series of heterogeneous 
cases reported here is just an indication that autoimmune 
thyroiditis may be frequently observed in concurrence 
with bipolar spectrum disorders. This does not necessary 
mean that thyroid antibodies play a direct role.
We speculate that there may be a wide spectrum of 
possibilities, varying from typical cases of mood dis-
orders with full response to treatment to treatment-
resistant cases and even to cases evolving into dementia. 
Obviously, the role of antibodies is more suspected in 
severe cases. Given the nature of our unit, the majority 
of cases regarded patients treated with lithium. In our 
lithium clinic, we have included the search for thyroid 
antibodies in the panel of laboratory tests since the late 
1980s. At that time, specific methods became routinely 
available and we had realized the relevance of thyroid 
autoimmunity in lithium-related hypothyroidism (Boc-
chetta et al. 1991).
In older patients from this series, the time relationship 
between onset of thyroiditis, onset of affective disorder, 
and treatment with lithium cannot be assessed. On the 
other hand, more recent cases (#7, #9, and #14) witness 
that thyroiditis may occur before lithium exposure.
The possible transition from “Hashimoto’s mood dis-
orders” to “Hashimoto’s encephalopathy” is just a matter 
of speculation. If one assumes that there is a direct role 
of thyroid antibodies in CNS, any presentation is possi-
ble from a mere psychiatric one to severe life-threatening 
neurologic encephalopathy.
However, the acceptance of a new disease entity is 
usually cautious. The communities of neurologists and 
endocrinologists are still doubtful regarding the entity 
Hashimoto’s encephalopathy (Chong et al. 2003; Fatoure-
chi 2005). We speculate that the community of psychia-
trists will be even more cautious. In his paper entitled 
“Hashimoto’s encephalopathy: myth or reality? An 
endocrinologist’s perspective,” Fatourechi (2005) stated: 
“Since the first description of a case of episodic encepha-
lopathy associated with Hashimoto’s thyroiditis in 1966, 
many cases of corticosteroid-responsive encephalopathy 
associated with positive antithyroid antibodies, clinical 
Hashimoto’s thyroiditis, or spontaneous autoimmune 
thyroid failure have been reported. These patients have 
neurologic manifestations of encephalopathy unrelated 
to other known causes. The condition has thus been 
termed ‘Hashimoto’s encephalopathy’. The literature 
shows no proven association between thyroid disease 
and the neurologic process. Although the association of a 
common endocrinologic condition and a rare neurologic 
disease may occur by chance, this type of encephalopa-
thy probably has an autoimmune nature and thus is more 
likely to occur in the background of another autoimmune 
condition such as autoimmune thyroid disease. Until 
the pathogenesis of these coincident conditions is bet-
ter defined, the term ‘corticosteroid-responsive encepha-
lopathy associated with autoimmune thyroiditis’ is more 
accurate and descriptive than Hashimoto’s encepha-
lopathy. Advances in the field may clarify this seemingly 
inconsistent terminology.”
A decade later, the same conclusion can be applied 
to cases with prominent psychiatric presentation, as 
those described in this paper. In any case, even the term 
SREAT must be considered provisional as it represents 
an example of “criterium ex adiuvantibus” which refers to 
the process of making an inference about disease causa-
tion from an observed response of the disease to a treat-
ment. It must be noted that, both in the psychiatric (this 
review) and in the neurological setting [see, for exam-
ple, Katoh et al. (2007) for a case with antibodies against 
the aminoterminal region of alpha-enolase], there have 
been cases with autoimmune thyroiditis which resolved 
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without undergoing corticosteroid therapy and there may 
have been a publication bias against steroid-non-respon-
sive cases.
Diagnostic procedures
The procedures in both previous case reports and in 
this case series have not been systematic, as they have 
reflected the availability of methods over the last two 
decades. Procedures might have also been influenced by 
the appearance of relevant literature reports. An example 
is the replacement of 99mTc-ECD with 99mTc-HMPAO as 
SPECT tracers.
It must be said that, by contrast with the severe cases of 
Hashimoto’s encephalopathy, pure psychiatric presenta-
tion may result in lack of further diagnostic procedures. 
An exception may be represented by treatment-refrac-
tory mood disorders or apparently unusual associations 
(mania with hypothyroidism).
In our own published case report (Bocchetta et  al. 
2007b) brain SPECT showed cortical perfusion asymme-
try particularly between frontal lobes.
Nagamine et al. (2008) reported a case of Hashimoto’s 
encephalopathy induced by lithium in a woman with 
bipolar II disorder and history of lithium-induced thy-
rotoxicosis associated with silent thyroiditis. SPECT 
detected multiple areas of hypoperfusion, particularly in 
frontal, parietal, and occipital cortices. Encephalopathy 
resolved with methylprednisolone therapy.
However, it is noteworthy that cortical hypoperfu-
sion is also found in brain SPECT imaging from series 
of patients with euthyroid autoimmune thyroiditis, even 
in the absence of any treatment or clinical evidence of 
CNS involvement (Zettinig et al. 2003; Piga et al. 2004). 
Various degrees of defective tracer uptake have been 
observed in the three patients from this series who 
underwent brain SPECT (# 2, # 3, # 7), with an apparent 
correlation with the severity of the psychiatric disorder.
Another study reported parietal SPECT asymmetry 
in depressed patients in the presence of thyroid autoim-
munity (Hardoy et al. 2011).
Pilhatsch et  al. (2014) studied positron emission 
tomography with 18F-fluorodeoxyglucose in hypothy-
roid patients with autoimmune thyroiditis suffering 
from neuropsychiatric symptoms: serum levels of AbTG 
were significantly correlated with glucose metabo-
lism in the perigenual anterior cingulate cortex, a brain 
region previously shown to regulate affect and emotional 
homeostasis.
Potential mechanisms
The mechanisms involved in mood disorders associ-
ated with autoimmune thyroiditis are only a matter of 
speculation. Even with regard to cases of encephalopathy 
with severe neurological presentation, there is no evi-
dence of a pathogenic role for the antibodies, which are 
probably markers of some other autoimmune disorders 
affecting the brain. Nevertheless, antithyroid antibodies 
were in some cases detected in the cerebrospinal fluid 
(Ferracci et  al. 2003; Wakai et  al. 2004). The focal and 
global cerebral involvement has also been attributed to 
autoimmune-mediated cerebral vasculitis, with or with-
out immune complex deposition (Kothaner-Margeiter 
et al. 1996; Shaw et al. 1991), or to an anti-neuronal anti-
body-mediated mechanism (Takahashi et al. 1994). Oth-
ers view it as a non-vasculitic autoimmune inflammatory 
meningoencephalitis (Castillo et al. 2006). Blanchin et al. 
(2007) detected high levels of AbTPO in the cerebrospi-
nal fluid of patients with Hashimoto’s encephalopathy. 
Both sera from their patients and monoclonal AbTPO 
were able to bind monkey cerebellar cells. Moreover, 
monoclonal AbTPO reacted with normal human astro-
cytes from primary cultures. Moodley et  al. (2011) 
described the presence of antigenic targets for anti-TSH-
receptor IgG on human cortical neurons and anti-TG IgG 
in cerebral vasculature.
We have hypothesized that abnormalities in cortical 
perfusion, as seen with SPECT, may represent a patho-
genic link between thyroid autoimmunity and mood dis-
orders (Bocchetta et al. 2007b). Peripheral microvasculitis 
may be evidenced with nailfold capillaroscopy, which is 
consistent with the view that systemic inflammation 
might contribute to endothelial dysfunction in patients 
with autoimmune thyroiditis (Taddei et al. 2006).
Yoneda et  al. (2007) have suggested that antibodies 
against the amino terminal region of alpha-enolase play 
a role in Hashimoto’s encephalopathy. Because alpha-
enolase is expressed in vascular endothelial cells, autoan-
tibodies against this enzyme may be associated with 
vasculitis.
Drexhage et  al. (2011) reported a lack of anti-inflam-
matory T cell forces in patients with bipolar disorder who 
were also positive for thyroid autoimmune disease.
We would like to mention another similar autoimmune 
disorder involving CNS that has recently drawn the atten-
tion and whose presentation may be neurological and/
or psychiatric. This is associated with antibodies against 
subunits of the N-methyl-d-aspartate receptor (AbNM-
DAR) (for a review see León-Caballero et al. 2015). AbN-
MDAR have been involved in encephalitis (Kayser et al. 
2013) and in mania (Dickerson et  al. 2012), and have 
been found in excess among patients with different psy-
chiatric disorders (schizophrenia, schizoaffective, dis-
order, bipolar disorder, major depressive disorder) (for a 
meta-analysis see Pearlman and Najjar 2014).
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Interestingly, anti-NMDAR has also been found in psy-
chiatric patients with circulating antithyroid antibodies 
(Chiba et al. 2013).
Finally, it is noteworthy that a genetic association has 
been found between bipolar disorder and polymorphism 
of Toll-like receptor 4 gene, which plays a major role in 
innate immunity (Oliveira et  al. 2014). Moreover, in a 
stratified analysis, two alleles were found more preva-
lent in bipolar patients with autoimmune thyroiditis. 
The authors suggested that an increased susceptibility 
to infections and/or autoimmunity may be a mechanism 
underlying a subgroup of bipolar disorders.
Treatment
The first objective in the treatment of patients with auto-
immune thyroiditis is to ensure a euthyroid status. The 
presence of circulating thyroid antibodies in itself does 
not require any treatment. In our experience, long-term 
treatment with levothyroxine may result in negativization 
of antibodies. However, the latter event is exceptional, 
especially when titers are as high as in our case series. 
Therefore, we cannot provide any support to the hypoth-
esis that mood symptoms improve while antibody levels 
normalize.
In autoimmune thyroiditis presenting with mood dis-
orders (Table 3), thyroid hormone substitution has been 
used in case of hypothyroidism (Schmidt et  al. 1990; 
Mahmud et al. 2003; Stowell and Barnhill 2005; Tor et al. 
2007; Liu et al. 2011; Lin et al. 2013) or antithyroid drugs 
in case of hyperthyroidism (Bokhari et  al. 1998; Müssig 
et al. 2005).
It is noteworthy that treatment-resistant depression 
may respond to adjunctive therapy with thyroid hor-
mones (for a review see Bauer et  al. 2008). In patients 
with bipolar disorder, administration of supraphysiologic 
thyroid hormone has been suggested to improve depres-
sive symptoms by modulating function in components of 
the anterior limbic network (Bauer et al. 2015).
Cases of mania associated with hypothyroidism due to 
thyroid autoimmunity have been reported to respond to 
hormone substitution in combination with common anti-
manic drugs (Stowell and Barnhill 2005; Tor et al. 2007; 
Lin et al. 2013).
Cases of Hashimoto’s encephalopathy with severe neu-
rological symptoms may require immunotherapy (cor-
ticosteroids, immunoglobulins, plasmapheresis) (for a 
review see Schiess and Pardo 2008). In cases with psychi-
atric presentation (Table 3), corticosteroids may be nec-
essary as well (Mahmud et  al. 2003; Mussig et  al. 2005; 
Laske et  al. 2005; Nagamine et  al. 2008; Liu et  al. 2011; 
Lin et al. 2011).
Cummings et  al. (2007) reported a case of Hashi-
moto’s encephalopathy with neurological and psychotic 
symptoms in a 19-year-old man who underwent neu-
ropsychological testing before, during, and after steroid 
treatment. Behavioral and psychotic symptoms remitted 
before cognitive deficits, suggesting that the latter may 
be more appropriate for guiding the duration of steroid 
treatment.
Nevertheless, potential corticosteroid-induced depres-
sion, hypomania, or overt psychosis is to be taken into 
account (for a review on corticosteroid-induced neu-
ropsychiatric disorders, see Bhangle et al. 2013).
We have no data about response to steroids, except for 
the brief concurrent trial with methylprednisolone pre-
scribed by the dermatologist for recurrence of urticaria 
vasculitis during follow-up of our published case and a 
trial with corticosteroids (in case # 2 from this series) that 
was abandoned after a few weeks because of the onset of 
diabetes.
With regard to lithium treatment, circulating thyroid 
antibodies should be checked besides the common panel 
of thyroid function tests, as they are one of the risk fac-
tors for lithium-induced hypothyroidism (Bocchetta et al. 
2001; Kupka et al. 2002). As already mentioned, lithium 
effects on thyroid function have long been known (for 
reviews see Lazarus 1998; Bocchetta and Loviselli 2006).
It must also be said that lithium has been considered 
responsible for a case of Hashimoto’s encephalopathy 
(Nagamine et  al. 2008). Nevertheless, we reported that 
lithium can improve the course of a bipolar case with 
refractoriness possibly associated with autoimmune thy-
roiditis (Bocchetta et  al. 2007b). In any case, lithium is 
recommended in case of high suicide risk (for a review 
see Lewitzka et al. 2015). Interestingly, lithium possesses, 
among other properties, a regulatory effect of innate and 
adaptive immune responses via inhibition of glycogen 
synthase kinase-3 (Beurel et  al. 2010; Beurel and Jope 
2014).
With regard to other psychotropic medications, there 
were two cases from our series (# 3 and # 7) who had 
abnormalities of perfusion seen on SPECT and have 
proven responsive to clozapine. Interestingly, Ertugrul 
et al. (2009) found that clozapine treatment can increase 
frontal perfusion in patients studied with SPECT and 
that the increase is particularly evident in treatment 
responders.
Prospect
Given their potential role, circulating thyroid antibodies, 
whose methods of detection have currently become rou-
tinary, should be searched in patients with bipolar spec-
trum disorders.
With regard to other procedures, none appears cur-
rently to be specifically indicated because they await 
confirmation.
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We suggest that future studies investigate in particu-
lar abnormalities in perfusion: for example, if there are 
correlations between specifically involved areas and 
clinical presentation, outcome, and effect of treatments. 
Relevance of thyroid antibodies with neuroimaging 
abnormalities frequently observed in bipolar spectrum 
disorders, such as white matter hyperintensities in MRI 
(Gunde et al. 2011), should also be investigated.
Similarly, the role of other antibodies that have been 
reported to concur with thyroid antibodies is to be con-
firmed. For example, the search for antibodies against the 
amino terminal region of alpha-enolase, whose presence 
have been associated in particular with psychiatric pres-
entation of Hashimoto’s encephalopathy (Yoneda et  al. 
2007), and AbNMDAR should hopefully become part of 
routine procedures.
The following observations from this series are to be 
confirmed and clarified: the concurrence of thyroidi-
tis and mood disorder with persistent tremors and with 
other autoimmune disorders (diabetes, coeliac disorder, 
multiple sclerosis, Sjögren syndrome), which is, however, 
a common finding (Sardu et al. 2012).
Conclusions
As mood disorders and circulating thyroid antibodies 
are very prevalent in the population, their concomitant 
occurrence may be due to chance. Prevalence studies in 
clinical samples and in community studies are inconclu-
sive. However, based on family and twin studies and on 
case reports, a role of thyroid antibodies in bipolar spec-
trum disorders cannot be disregarded.
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